Beta1-Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial Fibrillation 英文参考文献.docVIP

下载本文档

2
0
约2.77万字
约 8页
2017-05-11 发布于上海
举报
版权申诉

Beta1-Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial Fibrillation 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Beta1-Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial Fibrillation 英文参考文献

Beta1-AdrenoceptorPolymorphismPredictsFlecainide ActioninPatientswithAtrialFibrillation AmirM.Nia1.,EvrenCaglayan1.,NatigGassanov1.,TomZimmermann1,OrhanAslan1 ,Martin Hellmich2,FiratDuru3,ErlandErdmann1,StephanRosenkranz1,FikretEr1* 1Department ofInternal MedicineIII,UniversityofCologne,Cologne,Germany,2Institute ofMedicalStatistics, InformaticsandEpidemiology, UniversityofCologne, Cologne,Germany,3ClinicforCardiology,UniversityHospitalZurich,Zurich,Switzerland Abstract Background: Antiarrhythmic action of flecainide is based on sodium channel blockade. Beta1-adrenoceptor (b1AR) activationinducessodiumchannelinhibition,too.Theaimofthepresentstudywastoevaluatetheimpactofdifferentb1AR genotypesonantiarrhythmicactionofflecainideinpatientswithstructuralheartdiseaseandatrialfibrillation. Methodology/Principal Findings: In 145 subjects, 87 with atrial fibrillation, genotyping was performed to identify the individualb1ARArg389GlyandSer49Glypolymorphism.Restingheartrateduringatrialfibrillationandsuccessofflecainide- induced cardioversion were correlated with b1AR genotype. The overall cardioversion rate with flecainide was 39%. The Arg389Arg genotype was associated with the highest cardioversion rate (55.5%; OR 3.30; 95% CI; 1.34–8.13; p =0.003) comparedtopatientswithArg389Gly(29.5%;OR0.44;95%CI;0.18–1.06;p=0.066)andGly389Gly(14%;OR0.24;95%CI 0.03–2.07; p=0.17) variants. The single Ser49Gly polymorphism did not influence the conversion rate. In combination, patientswithArg389Gly-Ser49Glygenotypedisplayedthelowestconversionratewith20.8%(OR0.31;95%CI;0.10–0.93; p=0.03).InpatientswithArg389Argvariantstheheartrateduringatrialfibrillationwassignificantlyhigher(11062.7bpm; p=0.03vs.othervariants)comparedtoArg389Gly(104.862.4bpm)andGly389Gly(96.965.8bpm)carriers.TheArg389Gly- Ser49Gly genotype was more common in patients with atrial fibrillation compared to patients without atrial fibrillation (27.6%vs.5.2%;HR6.98;95%CI;1.99–24.46;p,0.001). Conclusions:Theb1ARArg389Arggeno